UNDERSTANDING MORPHOLOGICAL CHANGES IN THE OVARIES AFTER CHEMOTHERAPY: IMPLICATIONS AND IDEAS
- 1. Fergana Medical Institute of Public Health
Contributors
- 1. Fergana Medical Institute of Public Health
Description
Chemotherapy, the cornerstone of cancer treatment, often leads to unintended consequences, including significant changes in ovarian morphology. The ovaries, crucial female reproductive organs, undergo profound structural alterations after chemotherapy, impacting fertility, hormonal balance, and overall reproductive health. This dissertation comprehensively analyzes the morphological changes induced by chemotherapy in the ovary, elucidates their underlying mechanisms, and explores implications for fertility preservation strategies. Through a systematic review of existing literature, combined with clinical observations and experimental data, this study aims to provide an in-depth understanding of the effects of chemotherapy on ovarian morphology and its broader implications for women's health. By shedding light on the complex interaction between cancer treatment and fertility, this dissertation aims to inform clinical practice, guide patient counseling, and stimulate further research in the field of oncofertility.
Files
фулл артикл.pdf
Files
(1.3 MB)
Name | Size | Download all |
---|---|---|
md5:2cfdc1c5fcf633ed881cbdb30aaf71bf
|
1.3 MB | Preview Download |
Additional details
Dates
- Accepted
-
2024-07-11
References
- 1. Nguyen HN, Averette HE, Hoskins WJ, et al. National survey of ovarian cancer. Cancer. 1993;72:3663-3670.
- 2. Griffiths CT. Surgical resection of tumor mass in primary treatment of ovarian cancer. J Natl Cancer Inst Monogr. 1975;42:101-104.
- 3. Brinkhaus M, Baak JP, Meyer GA, et al. Significance of quantitative pathological variables as prognostic factors in advanced ovarian cancer. J Clin Pathol. 1996;49:142-148.
- 4. Topchieva SV, Orel NF, Gorbunova VA. Clinical study of cyclophosphamide in disseminated ovarian cancer. In: Proceedings of the VI Russian National Congress Human and Medicine; 1999.
- 5. Neijt JP, Hansen M, Hansen SW, et al. Randomised phase III study comparing paclitaxel–cisplatin and paclitaxel–carboplatin in untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV. Proc ASCO. 1997;16:352a (abstract 1259).